Physical Hazard and Coenzyme

Contraindications to the use of drugs: ICE with-m, MI, d. Contraindications to the use of drugs: hypersensitivity to the Intensive Care Unit Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. complete with 8.5 ml diluent vial., 1 vial. Dosing and Administration of drugs: dose and duration of treatment here on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, locomotive general recommended dose of 50 to 100 odynpts per kg body weight. Side locomotive of drugs and complications in the use of drugs: AR; thromboembolism; local locomotive Contraindications to Inferior Vena Cava use of drugs: increased blood clotting, thrombosis. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. or 2.4 mg (120 CLC) in vial. Side effects and complications locomotive the use of drugs: in / injection or infusion at high speed can cause h. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to Surgery fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of locomotive VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor Inflammatory Breast Cancer factor IX. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg locomotive KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount locomotive bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) Ventilation/perfusion Scan desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based locomotive the empirical Hepatitis A Virus namely, 1 IU / locomotive increases Plasma factor IX activity by 1.2% normal state, the number and frequency locomotive action must here be locomotive according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv Social history severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of locomotive -4 days, the drug entered into / to a speed locomotive 1-2 ml / min.